Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Baxter
Johnson and Johnson
Medtronic
Harvard Business School

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,573,438

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,573,438
Title: Inbred Maize line 2044BT
Abstract:The present invention is drawn to a novel DNA construct comprising an expression cassette having a constitutive promoter which functions in plant cells operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding a Cry 1Ab protein, and a terminator functional in plants and optionally further comprising a second cassette including a promoter which functions in plants operably linked to a maize alcohol dehydrogenase intron, a DNA sequence of a gene encoding for phosphinothricin acetyl transferase, and a terminator functional in plants wherein the two cassettes are transcribed in the same direction. Also provided are transgenic plants, particularly maize plants, having such a construct stably incorporated into their genomes.
Inventor(s): Mettler; Irvin J. (Richmond, CA), Mies; David (St. Joseph, IL)
Assignee: Syngenta Participations AG (Basel, CH)
Application Number:09/289,170
Patent Claims:1. Seed of maize inbred line 2044Bt having been deposited under ATCC Accession No. 203943, further comprising a nucleic acid construct with a first expression cassette comprising in operable linkage: (i) a CaMV 35S promoter, wherein said promoter is the sequence described in SEQ ID NO: 1; (ii) a maize alcohol dehydrogenase intron, wherein said intron is the sequence described in SEQ ID NO: 2; (iii) a DNA molecule encoding an insecticidal Cry1Ab protein toxin, wherein said DNA molecule encoding an insecticidal Cry1Ab protein toxin is the sequence described in SEQ ID NO: 3; and (iv) a NOS terminator, wherein said terminator is the sequence described in SEQ ID NO: 4.

2. An isolated seed of claim 1.

3. The seed of claim 1, wherein the nucleic acid construct further comprises a second expression cassette comprising in operable linkage: (i) a CaMV 35S promoter, wherein said promoter is the sequence described in SEQ ID NO: 5; (ii) a maize alcohol dehydrogenase intron, wherein said intron is the sequence described in SEQ ID NO: 6; (iii) a DNA molecule encoding a phosphinothricin acetyl transferase, wherein said DNA molecule encoding a phosphinothricin acetyl transferase is the sequence described in SEQ ID NO: 7; and (iv) a NOS terminator, wherein said terminator is the sequence described in SEQ ID NO: 8.

4. A maize plant, and parts thereof, of inbred line 2044Bt, seed of said line having been deposited under ATCC Accession No. 203943, said maize plant further comprising a nucleic acid construct with a first expression cassette comprising in operable linkage: (i) a CaMV 35S promoter, wherein said promoter is the sequence described in SEQ ID NO: 1; (ii) a maize alcohol dehydrogenase intron, wherein said intron is the sequence described in SEQ ID NO: 2; (iii) a DNA molecule encoding an insecticidal Cry1Ab protein toxin, wherein said DNA molecule encoding an insecticidal Cry1Ab protein toxin is the sequence described in SEQ ID NO: 3; and (iv) a NOS terminator, wherein said terminator is the sequence described in SEQ ID NO: 4.

5. Pollen of the plant of claim 4.

6. An ovule of the plant of claim 4.

7. A maize plant, or parts thereof, having all the genotypic and phenotypic characteristics of a plant of inbred line 2044Bt according to claim 4, seed of said line having been deposited under ATCC Accession No: 203943.

8. A method for producing maize seed comprising crossing a maize plant according to claim 4 with itself or another maize plant according to claim 4.

9. A method for producing hybrid maize seed comprising crossing a maize plant according to claim 4, with a different maize plant to form hybrid maize seed.

10. Hybrid seed produced by the method of claim 9.

11. Hybrid maize plant, or parts thereof, grown from the seed of claim 10.

12. The nucleic acid construct according to claim 4, wherein the nucleic acid construct further comprises a second expression cassette comprising in operable linkage: (i) a CaMV 35S promoter, wherein said promoter is the sequence described in SEQ ID NO: 5; (ii) a maize alcohol dehydrogenase intron, wherein said intron is the sequence described in SEQ ID NO: 6; (iii) a DNA molecule encoding a phosphinothricin acetyl transferase, wherein said DNA molecule encoding a phosphinothricin acetyl transferase is the sequence described in SEQ ID NO: 7; and (iv) a NOS terminator, wherein said terminator is the sequence described in SEQ ID NO: 8.

Details for Patent 6,573,438

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2017-03-14
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2017-03-14
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Merck
Mallinckrodt
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.